From Novel Biotechnology Platform to Globally Competitive Cancer Company: Proacta Inc.
centre-de-cas_hec.png

From Novel Biotechnology Platform to Globally Competitive Cancer Company: Proacta Inc.

8,00 $50,00 $

CASE STUDY. Proacta Inc., a private New Zealand-based biotechnology start-up focused on developing novel cancer therapeutics, faced a critical decision in 2004.

Pour acheter une licence « Licence par enseignement », vous devez vous enregistrer et être approuvé par notre administration.

UGS : 1388 Catégories : , Étiquettes : , ,

Produit

Summary

Proacta Inc., a private New Zealand-based biotechnology start-up focused on developing novel cancer therapeutics, faced a critical decision in 2004. Preclinical experiments of the company’s lead compound, PR-104, had produced promising results in prostate cancer and other solid tumours models, suggesting a potential path for clinical development towards commercial approval. The company was started by its scientific founders and had secured initial venture capital financing that opened up the potential to advance the technology to human clinical trials, which would require significant additional capital. In urgent need of additional funding to advance into human clinical trials, Proacta’s CEO visited 35 venture capital companies and alliance partners internationally. This decision-based case focuses on whether Proacta should raise more funds within New Zealand alone, syndicate a venture capital round with international investors, or seek a trade sale of the company.

Additionnal information

Teaching notes are available for teachers only. Contact HEC’s Case Centre for more information.

Information complémentaire

Année

2010

Éditeur

Centre de Cas HEC Montréal

Format

PDF

Industrie

Entrepreneurship, biotechnology, Strategy, Venture capital

Institution

HEC Montréal

Langue

Anglais

Nombre de pages

22

Taille

1211 ko

Numéro centre de cas

9 40 2010 037

Parution

Revue Internationale de Cas en Gestion (RICG)

Licence

Enseignement par professeur, Utilisation personnelle

Notes pédagogiques

Oui (pour professeurs)

Annexe

Oui

Avis

Il n’y pas encore d’avis.

Soyez le premier à laisser votre avis sur “From Novel Biotechnology Platform to Globally Competitive Cancer Company: Proacta Inc.”